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Transforming growth factor b(TGF-b) is an important regulator of
cell proliferation, differentiation and formation of extracellular
matrix (Roberts and Sporn, 1990; Moses, 1992; Kingsley, 1994).
The effects of TGF-bare mediated through binding to two ubiqui-
tously expressed receptors, TGF-breceptor type I (RI), and type II
(RII). RI and RII contain cytoplasmic serine/threonine kinase
domains and act in concert by heterodimerization (Wrana et al,
1994). One of the most pronounced effects of TGF-bin vitro is
growth inhibition of ectodermally derived cells (for review see
N¿rgaard et al, 1995). Some carcinomas are resistant to the growth
inhibitory effect of TGF-b, which in several cases has been
ascribed to lack of RII (Geiser et al, 1992; Inagaki et al, 1993;
N¿rgaard et al, 1994; Park et al, 1994). Recently, it was shown that
TGF-b1 acts as a growth inhibitor of carcinomas in vivo, at least
during early tumour growth (Cui et al, 1994, 1996; Pierce et al,
1995). In colon and gastric cancer, showing the replication error
phenotype, a high incidence of mutations in the poly-adenosine
(poly-A) tract of the RII gene was found leading to loss of RII
(Markowitz et al, 1995).
Lung cancer is divided into small cell lung cancer (SCLC) and
non-small cell lung cancer (NSCLC). Both types are characterized
by gross chromosomal rearrangements of which loss of hetero-
zygosity at the short arm of chromosome 3 is very frequent
(Mitsudomi et al, 1996; Todd et al, 1997). Interestingly, the RII
gene has been reported to map to chromosome 3p22 (Mathew et
al, 1994) and nearby loci have been found to be hypermethylated
in SCLC (Makos et al, 1995). Of 35 SCLC and NSCLC tumour
specimens with chromosome 3p loss examined for RII mutations,
only one SCLC tumour harboured a mutation in the poly-A tract.
The SCLC tumour showed a replication error phenotype (Tani et
al, 1997). Mutations in the poly-A tract of the RII gene therefore
seem to be infrequent in lung cancer.
We have previously shown that a number of SCLC cell lines did
not express RII protein (Damstrup et al, 1993), rendering them
resistant to the growth inhibitory effect of TGFb1 (N¿rgaard et al,
1994, 1996). In this report we characterized the expression of RNA
for RII in a panel of 21 SCLC cell lines and found that 16 cell lines
showed very weak expression. In one cell line we identified a muta-
tion generating a stop codon which predicts synthesis of a truncated
RII protein lacking the serine/threonine kinase domain. This partic-
ular type of mutation has been linked to exposure to benzo[a]-
pyrene, a component of cigarette smoke. We investigated whether
lack of RII transcript was due to hypermethylation of the promoter,
but found that this was not the case. In two cell lines Southern blot
analysis revealed an altered restriction pattern of the RII gene, but
treatment with 5-aza-2¢-deoxycytidine (5-azaCdR) did not increase
RII expression. We conclude that in the majority of SCLC cell
lines, the RII gene and promoter is intact. However, interestingly,
the nature of the found mutation suggests that it could be attributed
to cigarette smoking.
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SummaryTransforming growth factor b(TGF-b) exerts a growth inhibitory effect on many cell types through binding to two types of
receptors, the type I and II receptors. Resistance to TGF-bdue to lack of type II receptor (RII) has been described in some cancer types
including small cell lung cancer (SCLC). The purpose of this study was to examine the cause of absent RII expression in SCLC cell lines.
Northern blot analysis showed that RII RNA expression was very weak in 16 of 21 cell lines. To investigate if the absence of RII transcript was
due to mutations, we screened the poly-A tract for mutations, but no mutations were detected. Additional screening for mutations of the RII
gene revealed a GG to TT base substitution in one cell line, which did not express RII. This mutation generates a stop codon resulting in
predicted synthesis of a truncated RII of 219 amino acids. The nature of the mutation, which has not previously been observed in RII, has
been linked to exposure to benzo[a]-pyrene, a component of cigarette smoke. Since RII has been mapped to chromosome 3p22 and nearby
loci are often hypermethylated in SCLC, it was examined whether the lack of RII expression was due to hypermethylation. Southern blot
analysis of the RII promoter did not show altered methylation patterns. The restriction endonuclease pattern of the RII gene was altered in two
SCLC cell lines when digested with Sma1. However, treatment with 5-aza-2¢-deoxycytidine did not induce expression of RII mRNA. Our
results indicate that in SCLC lack of RII mRNA is not commonly due to mutations and inactivation of RII transcription was not due to
hypermethylation of the RII promoter or gene. Thus, these data show that in most cases of the SCLC cell lines, the RII gene and promoter is
intact in spite of absent RII expression. However, the nature of the mutation found could suggest that it was caused by cigarette smoking.
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Cell lines
SCLC cell lines were cultured in 150 cm2 culture flasks at 37°C
under standard conditions in medium containing 10% heat inacti-
vated fetal calf serum (FCS; Gibco BRL) without antibiotics. All
cell lines were routinely tested for mycoplasma contamination and
were found negative. Eight cell lines (DMS) were established at
Dartmouth Medical School (Hanover, NH, USA) and cultured
in Waymouth medium (GIBCO). Seven cell lines (GLC) were
established at Groningen Lung Cancer Centre (Groningen, The
Netherlands), two cell lines (NCI) were established at the National
Cancer Institute (Bethesda, MD, USA), and two cell lines (24H and
86M1) were established in Marburg, Germany. They were cultured
in RPMI-1640 (GIBCO). Finally, two cell lines (CPH) were estab-
lished in our own laboratory (Copenhagen, Denmark) and cultured
in Eagle￿s minimum essential medium (EMEM; GIBCO). The
origin and establishment of the cell lines have previously been
described in (Pettengill et al, 1980; Carney et al, 1985; De Leij et al,
1985; Engelholm et al, 1986; Berendsen et al, 1988; Vincent et al,
1997). Primary human foreskin fibroblasts (HFF; a gift from O
Pettengill, Dartmouth Medical School) were grown in Hanks basal
medium Eagle (BME; GIBCO). Cells for investigations were
harvested during exponential growth, washed in phosphate-
buffered saline (PBS) (Dulbeccos; GIBCO), centrifuged at 300 g,
immediately frozen in liquid nitrogen, and stored at — 80°C.
RNA extraction, electrophoresis and blotting
Total RNA was isolated by use of TRIzol8LS REagent
(GibcoBRL, Life Technologies) as recommended. Subsequent
Northern blot analysis was performed as previously described
(N¿rgaard et al, 1995). The Northern blots were analysed by
phosphor imager (STORM, Molecular Dynamics). The blots were
hybridized with a 32P-labelled RII probe, a 930 bp PstI—SacI frag-
ment of the cloned 4.5 kb H2-3FF human cDNA, kindly provided
by HY Lin (Lin et al, 1992). To ensure equal loading of RNA
present on the membrane, the blots were hybridized with a 32P-
labelled glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
probe, a 1.1 kb cDNA fragment purchased from Clontech
hybridizing to a single ~ 1.4 kb mRNA.
SSCP analysis
From each cell line, cDNA was obtained by reverse transcriptase
polymerase chain reaction (RT-PCR) according to recommenda-
tions (1st Strand cDNA Synthesis Kit for RT-PCR, Boehringer
Mannheim). A 269 basepair (bp) GAPDH fragment was generated
by PCR to test the cDNA reaction by use of the primers described in
Liabakk et al (1996). A 1678 bp RII fragment (from bp 35 to 1713)
was generated by PCR with the primers: 5¢-GCACATCGTCCT-
GTGGACGCGTA and 5¢-CCTGCCCCATAAAGAGCTATTTGG.
For subsequent generation of 250 to 363 bp fragments the
following primers were used:
From bp — 304 to 59: 5¢-GCGCTGAGTTGAAGTTGAGTGAGT
5¢-ATACGCGTCCACAGGAACGATGTGC.
In this case single-stranded confirmational polymorphism
(SSCP) was performed on PCR fragments generated utilizing
genomic DNA as template.
From bp 35 to 310: 5¢-GCACATCCTGTGGACGCGTA
5¢-GGTCATGGGAAACTGTCTCT.
From bp 242 to 543: 5¢-GGAAGTCTGTGTGTGGCTG-
TATGG
5¢-CAGATATGGCAACTCCCAGTGG.
From bp 491 to 780: 5¢-ATAAGTGACAGGCATCAGC
5¢-CCTTATAGACCTCAGCAAAGCG.
From bp 705 to 1011: 5¢-AACCACAACACAGAGCTGCTGC
5¢-TACTCCTGTAGGTTGCCCTTGC.
From bp 943 to 1193: 5¢-CGGAGTTGGGGAAACAATACTGG
5¢-AAAGTCACAC-AGGCAGCAGG.
From bp 1149 to 1405: 5¢-AATATCCTCGTGAAGAACGACC
5¢-TCTTTTACTTCTCCCACTGC
From bp 1356 to 1683: 5¢-GTGCTCTGGGAAATG-ACATCTCG
5¢-AGCCGTCTTCAGGAATCTTCTCC.
PCR comprised 30 cycles at 94°C for 30 s, 55—60°C for 1 min,
and 72°C for 1 min to generate the 250—327 bp fragments and 2 min
for the 1678 bp fragment. The PCR reactions were carried out with
Thermoprime Plus DNA polymerase (Applied Biochemistry) in
standard solutions. SSCP analysis was performed using non-denatu-
rating 5% acrylamide gels with 0%, 5%, or 10% glycerol. The
running conditions were 400 V for 1.5—2.5 h at 5°C or 10°C using a
vertical electrophoresis apparatus (Hoefer, serie 600). The gels were
stained with SYBR green (Medinova) and analysed by a fluores-
cence imager (STORM, Molecular Dynamics).
DNA sequencing
DNA fragments, which showed aberrant migration in the SSCP
analysis were de novo amplified by PCR. PCR products were
purified using MicroSpin S-400 HR Columns (Pharmacia). The
fragments were sequenced by Thermo Sequenase 33P-labelled
terminator cycle sequencing kit (Amersham, Life Science). The
samples were run on a standard acrylamide/urea gel and auto-
radiography was subsequently performed.
Analysis of the poly-A tract
A fragment from bp 329 to 401 from each cell line was generated
by PCR as previously described (Myeroff et al, 1995) using
genomic DNA as template. The samples were electrophoresed on
a 6% acrylamide gel followed by autoradiography.
DNA extraction, electrophoresis and blotting
DNA was extracted with phenol and chloroform by standard
methods (Sambrook et al, 1989), and digested with the restriction
endonucleases (RE): BsmI with one of the following methylation
sensitive RE: SmaI, Bst4I, HinPI, AatII, each of which has one
recognition site in the 3¢-end of the promoter and the 5¢-end of the
RII untranslated region. Digestion was performed as recom-
mended by the supplier (New England Biolabs) using 10 U of each
methylation sensitive RE/mg DNA and incubation for 18 h. DNA
(10 mg/lane) was electrophoresed on 0.8% agarose gels and
transferred to charged nylon membranes (GeneScreenPlus,
NEN/DuPont). Prehybridization, hybridization and washing were
performed as recommended by the supplier. Washing stringency
was 2 ´ SSC, 1% sodium dodecyl sulphate twice for 30 min at
60°C. Southern blots were probed with both 32P-labelled full-
length RII cDNA probe and a probe for the promoter. The latter
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GTTGCCCTAGCAAGA and 5¢-ATACGCGTCCACAGGAAC-
GATGTGC, which generated a fragment of 1306 bp covering the
region from nucleotide —1247 to 59. The template was genomic
DNA from HFF. Membranes were exposed to X-ray film
(Amersham) at — 80°C with an intensifying screen for 7 days.
Treatment with 5-azaCdR
Two cell lines showing altered RE-pattern with digestion with
SmaI, DMS 79, DMS 114 (both RII-negative), GLC 2 (RII-nega-
tive), and CPH 54A (RII-positive) were treated with 0.5, 0.75 and
2.0 mM 5-azaCdR (Sigma). The cells were treated for two
doubling times (respectively 83, 31, 26 and 43 h for each cell line).
The cells were harvested as described above at start, at one
doubling time and at two doubling times. To demonstrate a
possible induction of RII, total RNA was isolated by use of
TRIzol8LS REagent (GibcoBRL, Life Technologies) as recom-
mended. cDNA was obtained as described in SSCP analysis, and
expression of the receptor was detected by use of the above
mentioned primers generating a 508 bp 5¢-end transcript.
RESULTS
RII mRNA expression
Expression of RII mRNA was examined in 21 SCLC cell lines by
Northern blot analysis. The cell lines CPH 54A, CPH 54B, GLC
16, GLC 19 and DMS 273 expressed significant amounts of a
~5.5 kb mRNA for RII, whereas the rest of the cell lines showed
very weak expression (Figure 1). This correlated with previous
findings where RII protein expression was detected by chemical
cross-linking (Damstrup et al, 1993).
Screening for mutations of RII
It has previously been reported that mutations in the poly-A tract
of the RII gene have been associated with reduced, or lack of, RII
transcript (Markowitz et al, 1995) and hence we analysed the cell
lines for mutations in the poly-A tract (nucleotides 383—392) but
found no alterations (data not shown). Next we screened the RII
gene for mutation by SSCP analysis followed by sequencing. In
two cell lines, GLC 26 and DMS 456, the fragment representing
bp 491—780 migrated aberrantly (Figure 2). Subsequent
sequencing revealed a mutation in DMS 456. The mutation was a
GG to TT base substitution at nucleotides 658—659 (Figure 3A).
This substitution converts the wild-type glutamic acid to a stop
codon at amino acid 220 in exon 4 (Figure 3B). The presence of
the mutation was confirmed at the level of genomic DNA. The
transcript mutated in the serine/threonine kinase domain encodes a
predicted inactive RII receptor if translated. The aberrant
migrating band in GLC 26 was of lower molecular weight than in
case of DMS 456 (Figure 2). The band was reproduced at several
occasions, but it is presumably of no significance, since
sequencing did not reveal any mutation in GLC 26.
Analysis for altered methylation pattern
To investigate the reason for lack of RII transcript in 16 of the 21
SCLC cell lines, we examined all the SCLC cell lines for altered
methylation pattern in the 3¢-end of the promoter and the 5¢-end of
the untranslated region of the RII gene. This region fulfills the
criteria for a C/G island, having a C/G content over 70%.
Digestion with four different methylation sensitive REs, each
having recognition sites in the RII promoter, followed by Southern
blotting and hybridization with RII promoter probe, did not reveal
alterations of the promoter and with that no signs of altered
methylation of the RII promoter.
However, when the same Southern blots were hybridized with
the probe for the RII gene, it was found that in the case of the
SmaI/BsmI digestion the RE pattern was altered in two cell lines,
DMS 79 and DMS 114 (Figure 4). Digestion with the three other
combinations of REs showed an identical pattern in all the SCLC
cell lines indicating no gross structural changes of the RII gene
(data not shown). To examine if the altered RE pattern in DMS 79
and DMS 114 could be due to hypermethylation of the RII gene,
which could inactivate RII expression, we treated the cell lines
with 5-azaCdR. The response to 5-azaCdR treatment was evalu-
ated by detecting increased induction of RII RNA transcript.
Treatment with 5-azaCdR for two doubling times did not increase
transcription of the RII gene in either the two cell lines, or in
another RII-negative cell line (GLC 2), and transcription did not
increase in a RII-positive cell line (CPH 54A). We therefore
concluded that the silencing of the RII gene was not due to hyper-
methylation of the RII gene in DMS 79 and DMS 114. The obser-
vation that the two cell lines exhibited an altered RE pattern with
Mutation of RII in SCLC 1007
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Figure 1 Northern blot analysis of RII RNA in 21 SCLC cell lines. Total RNA (10 mg/lane) were electrophoresed in formaldehyde gel, transferred to nylon
membranes and subsequently hybridized with the human RII probe. The membrane was reprobed with GAPDH as internal standard. The cell lines CPH 54A,
CPH 54B, GLC 16, GLC 19 and DMS 273 express RII RNA, while the rest of the cell lines express RII RNA very weakly1008 S Hougaard et al
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Figure 2 SSCP gel run with the fragment from bp 491–780 of TGF-b–RII. Two RII-negative cell lines, GLC 26 and DMS 456, showed aberrantly migrating
fragments. Only in DMS 456, indicated by arrow, the fragment contained a mutation
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Figure 3 Mutations of the RII gene detected by DNA sequencing. (A) DNA fragments showing different mobility were re-amplified by PCR using the
corresponding set of primers and sequenced. In the SCLC cell line DMS 456 there was a GG®TT substitution in exon 4 at nucleotide 658–659. The
corresponding wild-type sequence is displayed in line N. The region containing the mutations are marked in brackets and the mutations are indicated in bold.
(B) Schematic representations of the sequence of wild-type RII mRNA and RII mRNA from DMS 456. The seven exons are indicated by numbers and the
predicted translated protein is illustrated with the signal sequence, the cysteine-rich sequence, the transmembrane (TM) and the serine/threonine kinase domaindigestion with SmaI could indicate that they contain an altered
sequence in an intron at a particular recognition site for SmaI.
Although the genomic structure of the RII gene has recently been
described (Lu et al, 1996), the sequence of the introns between the
seven exons has not been described. Accordingly, the precise
restriction pattern cannot be deduced.
DISCUSSION
We previously found that a number of SCLC cell lines did not
express RII protein (Damstrup et al, 1993) and that sensitivity to
the growth inhibitory effect of TGFb1 correlated to expression of
RII in five cell lines, while four cell lines not expressing RII were
resistant to TGFb1 (N¿rgaard et al, 1994, 1996). We examined 21
SCLC cell lines for expression of RII RNA. Sixteen of the 21 cell
lines showed weak expression of the RII RNA (Figure 1), which
correlated with the previously published protein expression
(Damstrup et al, 1993).
Mutations in the RII gene have been detected in human cancers
of the colon (Lu et al, 1995; Markowitz et al, Myeroff et al, 1995),
stomach (Park et al, 1994), endometrium (Myeroff et al, 1995), and
head and neck (Garrigue-Antar et al, 1995). These observations are
consistent with the proposal that RII is a tumour suppressor gene
and that inactivation of RII could be involved in human carcino-
genesis (Sun et al, 1994; Wang et al, 1995). RII mutations have
been detected frequently in the poly-A tract in tumours with
microsatellite instability (Lu et al, 1995; Markowitz et al, 1995;
Myeroff et al, 1995), suggesting that RII mutations occur preferen-
tially in microsatellite regions and in tumours with genomic insta-
bility. We did not find mutations in the poly-A tract, which is in
agreement with another study where only one of 15 SCLC tumour
specimens harboured a mutation at this site (Tani et al, 1997).
Mutations in the serine/threonine kinase domain of the RII gene
have also been found (Lu et al, 1995; Garrigue-Antar et al, 1997)
and in this paper we describe a mutation in exon 4, which results in
a truncated receptor lacking the kinase domain. However, this
mutation per se cannot account for the observed lack of RII RNA.
Recently, it has been described that 11 SCLC cell lines expressed
low levels of RII, and one cell line expressed a truncated RII tran-
script (de Jonge et al, 1997). The exact position of the
truncation was not determined, but it was located within exon 4.
However, the RII gene was screened for mutations in only four of
the cell lines. In contrast, we did not find a truncated RNA tran-
script, but rather a mutation that would lead to a truncated receptor
if translated.
From the present data it is not possible to deduce the succession
of pathogenetic events; i.e. whether the mutation was preceded by
silencing of the RII gene or vice versa. However, the type of muta-
tion implies that this may not be an in vitro phenomenon, since
occurrence of the G to T transversion in lung cancer mutational
hotspots was previously shown to correlate with the formation of
carcinogenic benzo[a]-pyrene metabolites found in cigarette
smoke (Denissenko et al, 1996). Benzo[a]-pyrene induces specific
mutations of the p53 gene and, interestingly, a similar G to T trans-
version was also found in the p53 gene of this particular SCLC
cell line (Abrahamsen et al, unpublished results), supporting the
assumption that the mutation of RII could have been a result of
cigarette smoking. To our knowledge this kind of mutation of the
RII gene has not been described previously.
In cancers, methylation of CpG islands in the promoter regions
of various genes is one established mechanism for regulating tran-
scriptional activity (Ferguson et al, 1995; Gonzalez-Zulaeta et al,
1995; Graff et al, 1995). The RII gene has been mapped to chro-
mosome 3p22 (Mathew et al, 1994) and tumour suppressor genes
associated with lung carcinogenesis have been suggested to be
present on chromosome 3p since loss of heterozygosity at this
chromosome occurs frequently in SCLC (Takenoshita et al, 1997).
Furthermore, it has been shown that nearby loci to the location of
the RII gene are hypermethylated in SCLC (Makos et al, 1995).
However, we did not find any altered restriction pattern of the RII
promoter. This is in agreement with a previous report where no
hypermethylation was found of the RII promoter (de Jonge et al,
1997). We found two cell lines with an altered restriction pattern of
the RII gene when digested with SmaI, but transcription of RII was
not increased with 5-azaCdR treatment. Thus, the RII gene of
these two cell lines must harbour an alteration at a SmaI site of
unknown position, possibly in an intron, since no mutations in
SmaI sites in the promoter or in the gene at exon 4 were found. The
Mutation of RII in SCLC 1009
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Figure 4 Southern blot performed with genomic DNA from 21 SCLC cell lines digested with BsmI and the methylation sensitive SmaI. The RII-negative cell
lines DMS 79 and DMS 114 showed an altered digestion patternsignificance of the alteration in these two cell lines in relation to
lack of RII expression remains uncertain. In gastric cancer cell
lines genomic alterations of the RII gene have been described,
both deletions and amplifications (Park et al, 1994). However, our
observation is not quite similar, since only a specific combination
of REs revealed a genomic alteration of the RII gene.
Our results indicate that alterations of the RII gene per se are not
a major genetic basis of the malignant phenotype of SCLC, in
contrast to gastrointestinal cancers (Markowitz et al, 1995). We did
not find a high frequency of RII mutations in SCLC and we did not
find an altered methylation pattern of the gene or promoter, which
could account for the observed lack of RII expression. The cause of
the silencing of the RII gene transcript is so far unknown, but may
be due to alterations or defects in the transcriptional apparatus.
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